Samalizumab is a novel, first-in-class, recombinant humanized anti-CD200 mAb, engineered to ablate effector function, that specifically binds to the immune checkpoint CD200, blocks receptor engagement and signaling and antagonizes CD200-driven immune suppression, thereby allowing the patient’s immune surveillance to detect tumor cells and mount an anti-tumor immune response. This evidence concerns the gene CD200 and neoplasm.